Mealey's (July 26, 2019, 12:18 PM EDT) -- SAN FRANCISCO — A lead plaintiff in a securities class action lawsuit against a drug company and three of its senior executives has failed to plead falsity and scienter in making his federal securities law claims, a Ninth Circuit U.S. Court of Appeals panel ruled July 23 in affirming a lower court’s dismissal of the lead plaintiff’s second amended complaint (In re Arrowhead Pharmaceuticals Inc. Securities Litigation, No. 17-56956, 9th Cir., 2019 U.S. App. LEXIS 21953)....